FDA Warns About Impulse-control Problems Associated with Mental Health Drug Abilify

May 3, 2016

On May 3, 2016 the FDA warned that compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported with the use of the antipsychotic drug Abilify®.[1]  The FDA is adding new warnings about all of these compulsive behaviors to the Abilify drug labels and patient Medication Guides.[2]  In 2012, European regulators required the makers of Abilify to warn consumers about the risk of uncontrollable impulses to gamble while taking the drug. [3]  Canadian regulators required a similar warning last year. [4]

Robins Kaplan LLP filed the first Abilify compulsive gambling cases in the United States in January 2016 and is actively litigating Abilify compulsive behavior cases.  Robins Kaplan LLP has 20 cases pending in federal courts across the country and 12 cases pending in New Jersey state court.  

Abilify, also known as aripiprazole, is an atypical anti-psychotic medicine prescribed to treat a variety of disorders including schizophrenia, bipolar disorder, depression, irritability, agitation, and mania.[5]  We are interested in speaking with individuals who have been prescribed Abilify and have developed a compulsive gambling addiction.

Robins Kaplan LLP is experienced with compulsive gambling suits.  We successfully represented more than 280 clients who developed compulsive gambling problems related to the Parkinson’s drug Mirapex.   

We are dedicated to giving our clients a voice against large pharmaceutical companies.  Our team of experienced mass tort attorneys, legal nurse consultants and other professionals have earned a national reputation for tirelessly fighting for justice for our clients.  We welcome calls from referring attorneys or potential clients.  Contact us at 1-800-553-9910 or at 1-612-349-8500.

[1] FDA Drug Safety Communication: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada), May 3, 2016; http://www.fda.gov/Drugs/DrugSafety/ucm498662.htm

[2] Id. 

[3] European Medicines Agency, Abilify: Procedural steps taken and scientific information after the authorization (last updated Dec. 6, 2014), available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000471/WC500020172.pdf.

[4] Safety information for antipsychotic drug Abilify and risk of certain impulse-control behaviors, Health Canada, Nov. 2, 2015, http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/55668a-eng.phpSummary Safety Review - ABILIFY and ABILIFY MAINTENA (aripiprazole) - Evaluating the Risk of Certain Impulse Control Behaviours, Health Canada, Nov. 2, 2015, http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/abilify-eng.php.

[5] Abilify Highlights of Prescribing Information.

Back to Top